Compare Dow Jones Industrial Average ETF (DIA) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs IDEXX Laboratories, Inc. — how do they compare? Dow Jones Industrial Average ETF trades at $536.91, while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: Dow Jones Industrial Average ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| DIA | IDXX | |
|---|---|---|
52-Week High | $542.79 | $766.68 |
52-Week Low | $444.64 | $526.44 |
Market Cap | — | $46.22B |
Sector | — | Health |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF) trades at $537.13, down 0.35% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF's dividend schedule includes upcoming payments of $1.41 and $0.28 per share through mid-2026. Recent market coverage highlights the Dow's milestone above 53,000 points, driven by financials and tech exposure, while broader ETF flows show strong investor interest in core index heavyweights amid defensive positioning.
Outlook remains positive given the Dow's blue-chip composition and recent market momentum, though risks include tech volatility and geopolitical tensions. The ETF offers stable dividend income and exposure to large-cap value stocks, but investors should monitor macroeconomic indicators and Fed policy for potential headwinds.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
